Enterprise Value
1.877B
Cash
343.2M
Avg Qtr Burn
-23.57M
Short % of Float
9.56%
Insider Ownership
8.30%
Institutional Own.
-
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Efruxifermin (FGF-21 mimetic) Details Non-alcoholic steatohepatitis Big Mover™ Suspected Mover™ Susp. Mover™ | Phase 2b Data readout | |
Efruxifermin (FGF-21 mimetic) Details Non-alcoholic steatohepatitis Big Mover™ Suspected Mover™ Susp. Mover™ | Phase 2b Data readout |